Orin Herskowitz is the President of the Mussallem CHD Alliance. Prior to joining, Orin was SVP of Applied Innovation at Columbia University, where he helped lead many of the innovation, entrepreneurship, tech transfer, and science-based economic development initiatives. Orin was also deeply engaged in many science, innovation and entrepreneurship efforts in New York City, New York State, and nationally, including serving as a board member at the Center for American Entrepreneurship; a member of the National Advisory Council on Innovation and Entrepreneurship in the U.S. Department of Commerce; an Innovation Fellow with Schmidt Futures; and an advisor to the National Science Foundation, ARPA-H, and other agencies. 

Eva Yao is the Chief of Staff of the Mussallem CHD Alliance. Eva is on a secondment from McKinsey & Company, where she was a Senior Business Analyst focusing on healthcare clients, predominantly healthcare provider organizations. Eva joined McKinsey out of Dartmouth College, where she studied Government and Psychology. During her undergraduate years at Dartmouth, Eva founded a healthcare nonprofit during COVID, providing financial support for students seeking mental health care.

Amelia Spiegelman is the Communications Assistant and Office Manager of the Mussallem CHD Alliance. Prior to joining, Amelia worked across multiple divisions of the Simons Foundation, including Science, Society & Culture and Mathematics and Physical Sciences divisions, where she supported various science engagement events. Before these roles, she conducted astrophysics research at NYU’s Center for Cosmology and Particle Physics, contributing to the classification of exoplanets using high-performance computing. Amelia graduated from NYU with a degree in Physics and minors in Astronomy and Studio Art. She is currently pursuing a master’s degree in data science through Harvard University.

Jonathan Birabaharan is the Research Strategy & Operations Manager for the Mussallem CHD Alliance. Prior to joining the Foundation, Jonathan was a Blavatnik Fellow at Yale Ventures, where he partnered with Yale faculty to translate cutting-edge science. In this role, he helped lead commercialization efforts across multiple therapeutic areas, including neurodegeneration, immunology, oncology, and women’s health, and supported the launch of several venture-backed startups. Jonathan has been deeply engaged in the life sciences innovation ecosystem throughout his career, spanning academia, startups, and venture capital. He previously worked with UPMC Enterprises, a corporate venture capital firm, LifeX, a Pittsburgh-based accelerator, and Resilient Life Sciences, a medtech startup. Earlier in his career, he held roles at GSK (via PPD) in clinical drug development and at Rockland Immunochemicals in antibody reagent development. Jonathan holds a PhD in Pharmaceutical Sciences and an MBA in Pharmacy Business Administration from the University of Pittsburgh, as well as a BS in Biochemistry and Molecular Biology.